US2023365594A1PendingUtilityA1

Thienopyrrole compounds

Assignee: GILEAD SCIENCES INCPriority: Apr 16, 2021Filed: Mar 8, 2023Published: Nov 16, 2023

Est. expiryApr 16, 2041(~14.7 yrs left)· nominal 20-yr term from priority

Inventors:Stephen E. Ammann Eda Canales Weng K. Chang Henok H. Kinfe Scott E. Lazerwith Michael L. Mitchell Yasamin Moazami Scott D. Schroeder Daniel Shore Christopher J. Swank

C07D 519/00C07D 495/04A61P 29/00A61K 31/496A61K 31/4706A61K 45/06A61P 37/00

69

PatentIndex Score

0

Cited by

0

References

0

Claims

Abstract

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Claims

exact text as granted — not AI-modified

1 - 175 . (canceled)

176 . A pharmaceutical composition comprising a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

177 . The pharmaceutical composition of claim 176 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

178 . The pharmaceutical composition of claim 176 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

179 . The pharmaceutical composition of claim 176 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

180 . The pharmaceutical composition of claim 176 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

181 . The pharmaceutical composition of claim 176 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

182 . The pharmaceutical composition of claim 176 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

183 . The pharmaceutical composition of claim 176 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

184 . The pharmaceutical composition of claim 176 , further comprising hydroxychloroquine, or a pharmaceutically acceptable salt thereof.

185 . The pharmaceutical composition of claim 184 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

186 . The pharmaceutical composition of claim 184 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

187 . The pharmaceutical composition of claim 184 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

188 . The pharmaceutical composition of claim 184 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

189 . The pharmaceutical composition of claim 184 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

190 . The pharmaceutical composition of claim 184 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

191 . The pharmaceutical composition of claim 184 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

192 . A method of treating an inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

193 . The method of claim 192 , wherein the inflammatory condition is systemic lupus erythematosus.

194 . The method of claim 193 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

195 . The method of claim 193 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

196 . The method of claim 193 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

197 . The method of claim 193 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

198 . The method of claim 193 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

199 . The method of claim 193 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

200 . The method of claim 193 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

201 . The method of claim 192 , wherein the inflammatory condition is cutaneous lupus erythematosus.

202 . The method of claim 201 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

203 . The method of claim 201 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

204 . The method of claim 201 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

205 . The method of claim 201 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

206 . The method of claim 201 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

207 . The method of claim 201 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

208 . The method of claim 201 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

209 . The method of claim 192 , wherein the inflammatory condition is lupus nephritis.

210 . The method of claim 209 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

211 . The method of claim 209 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

212 . The method of claim 209 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

213 . The method of claim 209 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

214 . The method of claim 209 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

215 . The method of claim 209 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

216 . The method of claim 209 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Join the waitlist — get patent alerts

Track US2023365594A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.